Evidence map›Paper›PMID 35340163›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2022

[Research Progress of Immunotherapy for Non-small Cell Lung Cancer 
with Drive Gene Mutation].

Renfang Deng, Yue Zeng, Yue Pan, Chunhong Hu, Fang Wu

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Renfang DengDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Yue ZengDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Yue PanDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Chunhong HuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Fang WuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Second Xiangya Hospital of Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has "driver gene mutations" and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after treatment. Previous studies demonstrated that immune checkpoint inhibitor could improve the prognosis of advanced-stage NSCLC and prolong the survival time. However, the efficacy of immune therapy varies in NSCLC patients with different immune and molecular features. The efficacy of immune therapy was controversial in NSCLC patients with driver gene mutation. The present review will summarize the immune characteristics of NSCLC patients with driver mutation and the directions of immunotherapy for patients with driver mutation.
.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmunotherapyMolecular Targeted TherapyMutationDriver geneImmune therapyLung neoplasms

Identifiers

PMID35340163
PMCPMC8976200
OpenAlexW4221078894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.